Tuli, Hardeep SinghSak, KatrinIqubal, AshifGarg, Vivek KumarVarol, MehmetSharma, UttamChauhan, AbhishekYerer, Mukerrem BetulDhama, KuldeepJain, ManjuJain, Aklank2024-01-162024-08-132024-01-162024-08-132022-04-26301485110.1007/s11033-022-07399-whttps://doi.org/10.1007/s11033-022-07399-whttp://10.2.3.109/handle/32116/2875As a landmark, scientific investigation in cytokine signaling and interferon-related anti-viral activity, signal transducer and activator of transcription (STAT) family of proteins was first discovered in the 1990s. Today, we know that the STAT family consists of several transcription factors which regulate various molecular and cellular processes, including proliferation, angiogenesis, and differentiation in human carcinoma. STAT family members play an active role in transducing signals from cell membrane to nucleus through intracellular signaling and thus activating gene transcription. Additionally, they are also associated with the development and progression of human cancer by facilitating inflammation, cell survival, and resistance to therapeutic responses. Accumulating evidence suggests that not all STAT proteins are associated with the progression of human malignancy; however, STAT3/5 are constitutively activated in various cancers, including multiple myeloma, lymphoma, breast cancer, prostate hepatocellular carcinoma, and non-small cell lung cancer. The present review highlights how STAT-associated events are implicated in cancer inflammation, angiogenesis and non-coding RNA (ncRNA) modulation to highlight potential intervention into carcinogenesis-related cellular processes. � 2022, The Author(s), under exclusive licence to Springer Nature B.V.en-USAngiogenesisChemoresistanceInflammationncRNASTATTherapeuticsReview